Bethany F Laden1, Catherine Bresee2, Amanda De Hoedt1, Kai B Dallas3, April Scharfenberg1, Roopali Saxena1, Justin F Senechal1, Kamil E Barbour4, Jayoung Kim3, Stephen J Freedland5, Jennifer T Anger6. 1. Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC. 2. Department of Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, CA. 3. Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA. 4. National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA. 5. Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, NC; Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA. 6. Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: Jennifer.Anger@cshs.org.
Abstract
OBJECTIVE: To examine the prevalence of comorbid conditions in a nationwide population of men and women with IC/BPS utilizing a more heterogeneous sample than most studies to date. METHODS: Using the Veterans Affairs Informatics and Computing Infrastructure, we identified random samples of male and female patients with and without an ICD-9/ICD-10 diagnosis of IC/BPS. Presence of comorbidities (NUAS [chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, migraines], back pain, diabetes, and smoking) and psychosocial factors (alcohol abuse, post-traumatic stress disorder, sexual trauma, and history of depression) were determined using ICD-9 and ICD-10 codes. Associations between these variables and IC/BPS status were evaluated while adjusting for the potential confounding impact of race/ethnicity, age, and gender. RESULTS: Data was analyzed from 872 IC/BPS patients (355 [41%] men, 517 [59%] women) and 558 non-IC/BPS patients (291 [52%] men, 267 [48%] women). IC/BPS patients were more likely than non-IC/BPS patients to have a greater number of comorbidities (2.72+/-1.77 vs 1.73+/-1.30, P < 0.001), experience one or more NUAS (chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, and migraines) (45% [388/872] vs. 18% [101/558]; P < 0.001) and had a higher prevalence of at least one psychosocial factor (61% [529/872] v. 46% [256/558]; P < 0.001). Differences in the frequencies of comorbidities between patients with and without IC/BPS were more pronounced in female patients. CONCLUSION: These findings validate the findings of previous comorbidity studies of IC/BPS in a more diverse population.
OBJECTIVE: To examine the prevalence of comorbid conditions in a nationwide population of men and women with IC/BPS utilizing a more heterogeneous sample than most studies to date. METHODS: Using the Veterans Affairs Informatics and Computing Infrastructure, we identified random samples of male and female patients with and without an ICD-9/ICD-10 diagnosis of IC/BPS. Presence of comorbidities (NUAS [chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, migraines], back pain, diabetes, and smoking) and psychosocial factors (alcohol abuse, post-traumatic stress disorder, sexual trauma, and history of depression) were determined using ICD-9 and ICD-10 codes. Associations between these variables and IC/BPS status were evaluated while adjusting for the potential confounding impact of race/ethnicity, age, and gender. RESULTS: Data was analyzed from 872 IC/BPS patients (355 [41%] men, 517 [59%] women) and 558 non-IC/BPS patients (291 [52%] men, 267 [48%] women). IC/BPS patients were more likely than non-IC/BPS patients to have a greater number of comorbidities (2.72+/-1.77 vs 1.73+/-1.30, P < 0.001), experience one or more NUAS (chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, and migraines) (45% [388/872] vs. 18% [101/558]; P < 0.001) and had a higher prevalence of at least one psychosocial factor (61% [529/872] v. 46% [256/558]; P < 0.001). Differences in the frequencies of comorbidities between patients with and without IC/BPS were more pronounced in female patients. CONCLUSION: These findings validate the findings of previous comorbidity studies of IC/BPS in a more diverse population.
Authors: Christian Temml; Clemens Wehrberger; Claus Riedl; Anton Ponholzer; Martin Marszalek; Stephan Madersbacher Journal: Eur Urol Date: 2006-08-30 Impact factor: 20.096
Authors: Ranak B Trivedi; Edward P Post; Haili Sun; Andrew Pomerantz; Andrew J Saxon; John D Piette; Charles Maynard; Bruce Arnow; Idamay Curtis; Stephan D Fihn; Karin Nelson Journal: Am J Public Health Date: 2015-10-16 Impact factor: 9.308
Authors: Lindsey C McKernan; Colin G Walsh; William S Reynolds; Leslie J Crofford; Roger R Dmochowski; David A Williams Journal: Neurourol Urodyn Date: 2017-10-09 Impact factor: 2.696
Authors: John N Krieger; Alisa J Stephens; J Richard Landis; J Quentin Clemens; Karl Kreder; H Henry Lai; Niloofar Afari; Larissa Rodríguez; Anthony Schaeffer; Sean Mackey; Gerald L Andriole; David A Williams Journal: J Urol Date: 2014-10-22 Impact factor: 7.450
Authors: Kenneth M Peters; Scott E Kalinowski; Donna J Carrico; Ibrahim A Ibrahim; Ananias C Diokno Journal: J Urol Date: 2007-07-16 Impact factor: 7.450
Authors: J Richard Landis; David A Williams; M Scott Lucia; Daniel J Clauw; Bruce D Naliboff; Nancy A Robinson; Adrie van Bokhoven; Siobhan Sutcliffe; Anthony J Schaeffer; Larissa V Rodriguez; Emeran A Mayer; H Henry Lai; John N Krieger; Karl J Kreder; Niloofar Afari; Gerald L Andriole; Catherine S Bradley; James W Griffith; David J Klumpp; Barry A Hong; Susan K Lutgendorf; Dedra Buchwald; Claire C Yang; Sean Mackey; Michel A Pontari; Philip Hanno; John W Kusek; Chris Mullins; J Quentin Clemens Journal: BMC Urol Date: 2014-08-01 Impact factor: 2.264